This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

1. (Currently amended) A composition comprising a fused pyrrolocarbazole with the formula:

at least about 20% (w/w) of a polyoxyl stearate; and at least one polyethylene glycol.

- 2. (Original) The composition of claim 1 wherein the fused pyrrolocarbazole is present at a concentration of about 1 to about 100 mg/mL.
- 3. (Original) The composition of claim 2 wherein the fused pyrrolocarbazole is present at a concentration of about 1 to about 50 mg/mL.
- 4. (Canceled)
- 5. (Canceled)

DOCKET NO.: CP185B PATENT

**Application No.:** 10/718,077

6. (Currently Amended) The composition of claim 1 wherein the polyethylene glycol has a molecular weight from about 300 to about 8000 Daltons.

- 7. (Currently Amended) The composition of claim 6 wherein the polyethylene glycol has a molecular weight from about 400 to about 3350 Daltons.
- 8. (Currently Amended) The composition of claim 7 wherein the polyethylene glycol has a molecular weight from about 400 to about 1500 Daltons.
- 9. (Previously Presented) The composition of claim 1 wherein the polyethylene glycol is selected from PEG-400, PEG-600, PEG-1000, and PEG-1450.
- 10. (Cancelled)
- 11. (Currently Amended) The composition of claim 9 wherein the ratio of polyethylene glycol:polyoxyl stearate ranges from about 50:50 to about 80:20.
- 12. (Currently Amended) The composition of claim 11 wherein the ratio of polyethylene glycol:polyoxyl stearate is <u>about</u> 50:50.
- 13. (Currently Amended) The composition of claim 11 wherein the ratio of polyethylene glycol:polyoxyl stearate is about 80:20.
- 14. (Original) The composition of claim 1 comprising a polyethylene glycol mixture selected from PEG-400/PEG-1000, PEG-400/PEG-1450, PEG-600/PEG-1000, and PEG-600/PEG-1450.

**Application No.:** 10/718,077

15. (Currently Amended) The composition of claim 14 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is from about 50:50 to about 80:20.

- 16. (Currently Amended) The composition of claim 15 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is about 50:50.
- 17. (Currently Amended) The composition of claim 15 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is <u>about</u> 80:20.
- 18. (Currently Amended) The composition of claim 16 wherein the composition comprises PEG-400:PEG-1000:polyoxyl stearate in a ratio of <u>about</u> 25:25:50.
- 19. (Currently Amended) The composition of claim 16 wherein the composition comprises PEG-400:PEG-1450:polyoxyl stearate in a ratio of about 25:25:50.
- 20. (Currently Amended) The composition of claim 17 wherein the composition comprises PEG-400:PEG-1000:polyoxyl stearate in a ratio of about 40:40:20.
- 21. (Currently Amended) The composition of claim 17 wherein the composition comprises PEG-400:PEG-1450:polyoxyl stearate in a ratio of <u>about</u> 40:40:20.

Claims 22 – 26 (Cancelled)

Claims 27 –46 (Cancelled)

47. (New) The composition of claim 9 wherein the polyoxyl stearate is polyoxyethylene (40) stearate.

DOCKET NO.: CP185B PATENT

**Application No.:** 10/718,077

48. (New) The composition of claim 15 wherein the polyoxyl stearate is polyoxyethylene (40) stearate.

- 49. (Presently amended) A method of treating of acute myelogenous leukemia comprising administering a composition according to claim 1 to a subject in need thereof.
- 50. (New) A method of treating prostate cancer comprising administering a composition according to claim 1 to a subject in need thereof.